One of Eli Lilly's potential competitors in the weight loss market just reported unimpressive trial results. The company could benefit from the government coverage of its weight loss medicines.

Among drugmakers, there are already signs of pushback. David Ricks, the chair and chief executive of Eli Lilly, speaking at The New York Times’s DealBook Summit, said his $750 billion company ...

Singer-songwriter Will Kennedy moves through grief in delicate and unsparing ways using the simple sounds of lo-fi indie rock. When the lily of the valley starts to bloom, it’s one of the surest ...

picture alliance / Contributor / Getty Images Eli Lilly and Novo Nordisk shares rose Tuesday after the Biden administration proposed expanding coverage of the companies' weight-loss drugs in ...

Eli Lilly shares were up more than 4% at last check. Get Monthly Picks of Market's Fastest Movers Eli Lilly And Co LLY shares are trading higher Tuesday after the Biden-Harris Administration ...

Biden proposes expanding coverage for anti-obesity drugs Novo shares jump as much as 4.9%, Lilly stock also gains Amgen weight-loss drug trial results miss market expectations Nov 26 (Reuters ...

A spokesperson for Sanofi confirmed plans to implement a similar model as those proposed by Johnson & Johnson and Eli Lilly — to give hospitals rebates for eligible drugs in program, called 340B ...

Lilly’s 20% increase came after it had recorded five straight quarters of at least 28% YOY revenue gains. The company pointed out that its Q3 figure was skewed by its $1.4 billion sale of its ...

Josh previously revealed it had been at least four months since he and Lily last had sex, and Lily claimed they'd had sex no more than five times Abigail Adams is a Human Interest Writer and ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks Jim Cramer was talking about. Jim Cramer, host of Mad Money, recently ...

As the confetti was still falling in Las Vegas on another Kansas City Chiefs' Super Bowl victory, general manager Brett Veach was faced with a difficult decision: Chris Jones or L'Jarius Sneed?

Pharmaceuticals stock Eli Lilly and Company (NYSE:LLY) is down by 23% since I last wrote about it in September. At the time, it appeared that the company could come out on top despite challenges ...